VMTF — VMT Scientific, Inc.
701 N. Green Valley Parkway Suite 200
Henderson, NV 89074
VMT Scientific, Inc. (OTC: VMTF)
Outstanding Shares: 180,650,000
Estimated Float: 5,000,000
State Of Incorporation: NV
Country Of Incorporation: USA
Company Officers: Eugene F. Koppenhaver, Sole Officer, Dir.
SEC Reporting Status: De-Registered
Standard Transfer & Trust Company, Inc.
2980 South Rainbow Blvd.
Las Vegas, NV 98146
Industry: Health / Biotechnology
VMT Scientific Inc. Announces Unilateral Development
Monday November 28, 6:01 am ET
LAS VEGAS, Nov. 28 /PRNewswire-FirstCall/ -- VMT Scientific Inc. (OTC: VMTF - News) announces that's its globally patented breakthrough technology known as the VasCir (TM) system has now begun development of it's hand, finger and limb units, as well as the feet. After fielding calls from desperate individuals facing amputations, their Doctors, requesting to be part of the trials as to help speed testing and Medical Centers worldwide. VMT Scientific Inc has moved its scheduled monolithic development into a unilateral phase, where all products will be developed along the same lines. It's a FACT that in 2003, it was estimated that over one half billion people worldwide suffer from some form of Diabetic or Pre-Diabetic condition, that will effect the normal blood flow to their extremities and compromise their health. Out of that half billion people, approx 40% of those will lead to amputations.
The VasCir (TM) System is predicted to reduce the number of PVD related amputations by 50% or more. VMT Scientific Inc's CTO states that there is no known technology that can establish blood flow to the extremities the same way the VasCir (TM) system can. Documented preliminary tests indicated that as much as a 300% increase in arterial blood flow to the treated limb in as little as 15 minutes. This life and limb saving arterial blood carries with it rich oxygen and nutrients that are necessary for proper limb health.
The World's demand for the VasCir (TM) system is staggering! Based on USA estimates, every 8 minutes an individual's foot is amputated and a staggering 2 million toes and fingers are amputated annually due to the effects of PVD!
The potential market for VMT Scientific Inc's patented technology is in the millions of units sold annually. The VasCir (TM) system goal is to earn FDA approval and to qualify as a Medicare reimbursable. VMT Scientific Inc. is poised for a healthy financial future as well as saving lives and limbs. If these projected estimates hold true, everybody wins, the patients, the Doctors, and the Stockholders.
Please visit VMT Scientific, Inc.'s Web site for more information: http://www.vmtf.org
This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. Technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientifics' future access to capital to sustain operations, achieve profitability, to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property and or continue as a going concern. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations.
Source: VMT Scientific Inc.
DISCLAIMER - Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information.